Cellectis (CLLS) Receivables (2014 - 2026)
Cellectis (CLLS) recorded quarterly Receivables of $5.2 million in Q1 2026, down 64.22% quarter-over-quarter from $14.4 million in Q4 2025, and down 34.55% on a YoY basis from $7.9 million in Q1 2025.
Cellectis (CLLS) Receivables (2014 - 2026) Analysis & Trends
Cellectis' Receivables history runs 13 years deep, the most recent figure standing at $5.2 million for Q1 2026.
- In Q1 2026, Receivables fell 34.55% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.2 million (down 34.55% YoY), while the FY2025 annual figure was $14.4 million, up 114.45% from the prior year.
- Receivables was $5.2 million for Q1 2026 at Cellectis, down from $14.4 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $21.8 million in Q1 2022 to a low of $393000.0 in Q3 2023.
- Historically, Receivables has averaged $6.8 million across 5 years, with a median of $6.7 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Receivables tumbled 96.21% in 2022, then surged 2744.78% in 2024.
- A 5-year view of Receivables shows it stood at $772000.0 in 2022, then retreated by 26.3% to $569000.0 in 2023, then soared by 1079.96% to $6.7 million in 2024, then soared by 114.45% to $14.4 million in 2025, then slumped by 64.22% to $5.2 million in 2026.
- The last three Receivables figures came in at $5.2 million (Q1 2026), $14.4 million (Q4 2025), and $8.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | 5.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.15 Mn |
| Dec 31, 2025 | 14.40 Mn |
| Sep 30, 2025 | 8.06 Mn |
| Jun 30, 2025 | 8.78 Mn |
| Mar 31, 2025 | 7.87 Mn |
| Dec 31, 2024 | 6.71 Mn |
| Sep 30, 2024 | 11.18 Mn |
| Jun 30, 2024 | 9.74 Mn |
| Mar 31, 2024 | 16.04 Mn |
| Dec 31, 2023 | 569,000.00 |
| Sep 30, 2023 | 393,000.00 |
| Jun 30, 2023 | 422,000.00 |
| Mar 31, 2023 | 1.12 Mn |
| Dec 31, 2022 | 772,000.00 |
| Sep 30, 2022 | 802,000.00 |
| Jun 30, 2022 | 2.60 Mn |
| Mar 31, 2022 | 21.84 Mn |
| Dec 31, 2021 | 20.39 Mn |
| Sep 30, 2021 | 349,000.00 |
| Jun 30, 2021 | 3.88 Mn |